BRAF and melanoma: In mice bearing melanoma PDX tumors harboring an AGK::BRAF fusion, tumor regression was observed in response to oral administration of tovorafenib for 14 days at dosage levels of 25 and 17.5 mg/kg daily assessed in two separate efficacy studies, respectively (Fig. 1A and B, respectively).